Scleroderma Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Scleroderma Therapeutics Market is segmented by Disease Type (Systemic Scleroderma and Localized Scleroderma), Drug Type, and Geography.

Home Industry Reports Healthcare Scleroderma Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts ...

Market Snapshot

Scleroderma Therapeutics Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.7 %
Scleroderma Therapeutics Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Scleroderma is a rare and chronic disease that affects around 2.5 million people across the world. The market for scleroderma therapeutics is expected to grow in the near future, owing to the factors, such as the rising prevalence of the disease and the focus of pharmaceutical companies, to come up with novel drugs.

  • In the United Kingdom, around 19,000 people had been diagnosed with Scleroderma in the year 2018, as stated by Scleroderma & Raynaud’s UK. In the United Kingdom, Scleroderma & Raynaud’s UK is the only charity, which has been dedicated to improving the lives of people suffering from Scleroderma in the country. Studies have suggested that the prevalence of the disease is more in African Americans, and it is four to nine times higher in women than in men.
  • Currently, there has been an improvement in the treatment of scleroderma toward managing complications and providing symptomatic relief. Disease-modifying treatment is widely being investigated for scleroderma, which has been aiming at inhibiting tissue fibrosis and vascular and immune system alterations, which are the three crucial components of disease pathogenesis. 
  • The upcoming therapies from pharmaceutical companies and future approvals of the same may boost the growth of the market studied.

Scope of the Report

Scleroderma is an autoimmune disease that affects the skin, blood vessels, muscles, and internal organs. The disease is usually caused due to an abnormal immune response. Therapies for this disease include immunosuppressive drugs and in some cases, glucocorticoids.

By Disease Type
Systemic Scleroderma
Localized Scleroderma
By Drug Type
Phosphodiesterase 5 inhibitors - PHA
Prostacyclin Analogues
Immunosuppressors
Endothelin Receptor Antagonists
Calcium Channel Blockers
Other Drug Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Immunosuppressors are Expected to Witness High Growth Over the Forecast Period

There is no complete cure for Scleroderma. However, scientists have suggested a few therapies that can be useful for people suffering from this disease. Immunosuppressants are the type of medication that helps reduce the symptoms of scleroderma. As the disease has been associated with the immune system, the immunosuppressants help the same by reducing the immune response from occurring. Immunosuppressors act to trigger the death of immune cells or prevent the production of more immune cells. One of the examples for immunotherapy is rituximab, which reduces the level of B-cells, a type of immune cells involved in the scleroderma.

As of now, immunosuppressants are not approved by the FDA for the treatment of scleroderma but they are given to the patients off-label. Some of the immunosuppressants used for scleroderma include Methotrexate, CellCept, Cytoxan, Imuran, cyclosporin, and Thymoglobulin. Several clinical trials are being done currently to investigate the efficacy of immunosuppressants, and the results of these clinical trials have suggested that immunosuppressants can be beneficial in treating scleroderma.

Hence, with the growing clinical trials and proven efficacy of the immunosuppressants, the market studied is expected to register growth in the future.

Scleroderma Therapeutics Market Share

North America Dominates the Market

North America is expected to hold the largest share for the scleroderma therapeutics market. This has been majorly attributed to the rising number of people suffering from these diseases and the developed healthcare sector, which allows access to novel therapeutics. In the United States, organizations, such as Scleroderma Foundation, have been working toward the management of disease and research on the same. As per this foundation, Scleroderma affects about 300,000 people in the United States, about one in every thousand. It has been observed that since the last decade, scleroderma has been intensified in the United States, therefore, there has been continuous research going on the country for developing a proper treatment for scleroderma. Rising clinical trials that have been resulting in a positive outcome are expected to come up with novel therapies that may boost studied market's growth.

Scleroderma Therapeutics Market Growth

Competitive Landscape

The market for scleroderma therapeutics is moderately competitive, and several big pharmaceutical companies have been involved in the market studied. As there is no curative drug available, these companies have been providing the drugs that reduce the symptoms of the disease. Few companies have their products in the pipeline, and few have been seeking approval from the FDA. With the growing R&D focus of these companies, it is expected that novel therapies may come into the market studied, and the competition may increase in the future.

Major Players

  1. Boehringer Ingelheim International GmbH

  2. Celgene Corporation

  3. arGentis Pharmaceuticals Llc

  4. Kadmon Holdings, Inc.

  5. Emerald Health Pharmaceuticals

Boehringer Ingelheim International GmbH, Celgene Corporation, arGentis Pharmaceuticals Llc, Kadmon Holdings, Inc., Emerald Health Pharmaceuticals

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Scleroderma

      2. 4.2.2 Raised Focus of Pharmaceutical Companies to Come up With Novel Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Regulatory and Reimbursement Issues

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease Type

      1. 5.1.1 Systemic Scleroderma

      2. 5.1.2 Localized Scleroderma

    2. 5.2 By Drug Type

      1. 5.2.1 Phosphodiesterase 5 inhibitors - PHA

      2. 5.2.2 Prostacyclin Analogues

      3. 5.2.3 Immunosuppressors

      4. 5.2.4 Endothelin Receptor Antagonists

      5. 5.2.5 Calcium Channel Blockers

      6. 5.2.6 Other Drug Types

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Boehringer Ingelheim International GmbH

      2. 6.1.2 Celgene Corporation

      3. 6.1.3 arGentis Pharmaceuticals LLC

      4. 6.1.4 Prometic Life Sciences Inc.

      5. 6.1.5 Kadmon Holdings Inc.

      6. 6.1.6 Emerald Health Pharmaceuticals

      7. 6.1.7 Cytori Therapeutics Inc.

      8. 6.1.8 Chemomab

      9. 6.1.9 Corbus Pharmaceuticals Holdings Inc.

      10. 6.1.10 Bayer AG

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Scleroderma Therapeutics Market market is studied from 2018 - 2026.

The Scleroderma Therapeutics Market is growing at a CAGR of 5.7% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Boehringer Ingelheim International GmbH, Celgene Corporation, arGentis Pharmaceuticals Llc, Kadmon Holdings, Inc., Emerald Health Pharmaceuticals are the major companies operating in Scleroderma Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!